ArticleProceedings of the National Academy of Sciences of the United States of America1999
RNA aptamers as effective protein antagonists in a multicellular organism.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 121 citations in OpenAlex.
- Integrated 'Shield-Spear' Biological Patch for Fibrosis-Free Bladder Reconstruction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Recent advances in aptamer discovery, modification and improving performance.Biochemistry and biophysics reports · 2024Review
- Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges.Cancers · 2023Review
- RNA-based cooperative protein labeling that permits direct monitoring of the intracellular concentration change of an endogenous protein.Nucleic acids research · 2021Article
- Chemical Modification of Aptamers for Increased Binding Affinity in Diagnostic Applications: Current Status and Future Prospects.International journal of molecular sciences · 2020Review
- A 50 year history of technologies that drove discovery in eukaryotic transcription regulation.Nature structural & molecular biology · 2019Review
- Multivalent Aptamers: Versatile Tools for Diagnostic and Therapeutic Applications.Molecules (Basel, Switzerland) · 2016Review
- Single neuron transcriptomics identify SRSF/SR protein B52 as a regulator of axon growth and Choline acetyltransferase splicing.Scientific reports · 2016Article
- Selection of RNA Aptamers Against Botulinum Neurotoxin Type A Light Chain Through a Non-Radioactive Approach.Applied biochemistry and biotechnology · 2016Article
- Highly Multiplexed RNA Aptamer Selection using a Microplate-based Microcolumn Device.Scientific reports · 2016Article
- Anti-Transcription Factor RNA Aptamers as Potential Therapeutics.Nucleic acid therapeutics · 2016Review
- Selective aptamer-based control of intraneuronal signaling.Angewandte Chemie (International ed. in English) · 2015Article
- A role for the serine/arginine-rich (SR) protein B52/SRSF6 in cell growth and myc expression in Drosophila.Genetics · 2015Article
- Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.World journal of hepatology · 2015Review
- Article
- A systematic study of the features critical for designing a high avidity multivalent aptamer.Nucleic acid therapeutics · 2013Article
- Development of temperature-sensitive mutants of the Drosophila melanogaster P-TEFb (Cyclin T/CDK9) heterodimer using yeast two-hybrid screening.Biochemical and biophysical research communications · 2013Article
- Multiplexed microcolumn-based process for efficient selection of RNA aptamers.Analytical chemistry · 2013Article
- Evolution of an inhibitory RNA aptamer against T7 RNA polymerase.FEBS open bio · 2012Article
- Rational design of a small molecule-responsive intramer controlling transgene expression in mammalian cells.Nucleic acids research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
RNA aptamers selected against proteins can be used to modulate specific protein function. Expression of such reagents in cells and whole organisms could provide a means of dissecting and controlling molecular mechanisms in vivo. We demonstrate that Drosophila B52 protein can be specifically inhibited in vitro and in vivo by a multivalent RNA aptamer. This inhibitory aptamer RNA binds B52 avidly and inhibits B52-stimulated pre-mRNA splicing. It can be expressed in cultured cells and whole animals in a stable form that accumulates up to 10% of total mRNA. It binds B52 in vivo and suppresses all phenotypes caused by B52 overexpression. The strategies presented here should prove general in design and expression of functional and therapeutic RNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.